Enterprise Therapeutics

UK - BrightonBiotechnology1 H-1B visas (FY2023)

Focus: Enterprise Therapeutics is a UK-based public biotech company specializing in respiratory treatments, with a heavily concentrated revenue model driven by ESBRIET (pirfenidone).

Respiratory

Profile data last refreshed 14h ago · AI intelligence enriched 14h ago

Funding Stage

PUBLIC

Open Jobs

0+8 this month

Growing — net +8 jobs in 30d

8 jobs added vs 0 removed. Steady team buildout.

About Enterprise Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Enterprise Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 in 5yr

BRISDELLE

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

ESBRIET

Respiratory (idiopathic pulmonary fibrosis implied)

$93M Part D

Peak

Help build intelligence for Enterprise Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Stable, peak-revenue product (ESBRIET) generating $93M in Part D spending with patent protection until 2037, providing salary security in the near term.
Early-stage respiratory pipeline (ETD001 in Phase 2 for Cystic Fibrosis) offers meaningful R&D contribution opportunities in a focused therapeutic area.
UK-based headquarters in Brighton provides access to a talent-rich biotech hub and potential for international collaboration in respiratory medicine.

Watch Out For

Severe business concentration risk: 82% of revenue from a single drug (ESBRIET) exposes you to patient population changes, competitive threats, and regulatory shifts without pipeline diversification.
Significant organizational instability: a WARN filing for 77-employee closure in Earth City, MO (Feb 2025) signals active restructuring and layoff risk despite being a public company.
Thin pipeline signal: only 2 internal programs in clinical phases (ETD001/002 for CF) plus heavy reliance on third-party/academic trials, suggesting limited internal R&D execution or capital allocation.
Zero open job postings suggests either hiring freeze, recent restructuring completion, or minimal growth trajectory—limiting near-term advancement or onboarding.

Generated by Claude from Enterprise Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Flagship product representing 82% of company revenue; established mechanism with patent protection through 2037, generating predictable but non-growth cash flow.

CROTAN

Scabies (scabicial and antipruritic)

$14M Part D

Post-LOE

Generic/post-LOE topical with modest revenue; minimal innovation or market expansion potential.

NAFTIN

Tinea pedis (interdigital fungal infection)

$2M Part D

LOE Approaching

Topical antifungal approaching loss of exclusivity; minimal revenue contribution and declining trajectory.

LOTRONEX

Irritable Bowel Syndrome

$1M Part D

LOE Approaching

5-HT3 antagonist with minimal market penetration; approaching LOE with negligible revenue impact.

RIDAURA

Rheumatoid Arthritis (gold-containing)

$994K Part D

LOE Approaching

Dated gold-based therapeutic with de minimis revenue and LOE risk; vestigial asset.

BETAPACE

Life-threatening ventricular arrhythmias

$677K Part D

LOE Approaching

Antiarrhythmic with minimal revenue; approaching LOE with limited clinical differentiation.

MOTOFEN

Diarrhea

$616K Part D

LOE Approaching

Antidiarrheal with de minimis revenue; approaching LOE with no growth potential.

ZANAFLEX

Spasticity in adults

$503K Part D

LOE Approaching

Alpha-2-adrenergic agonist for muscle spasticity with small revenue base; approaching LOE.

BETAPACE AF

Life-threatening ventricular arrhythmias

$224K Part D

LOE Approaching

Antiarrhythmic formulation variant with minimal market traction; approaching LOE.

ALA-SCALP

Scalp inflammation

$145K Part D

Post-LOE

Topical corticosteroid post-LOE with negligible revenue; commodity-level asset.

Pipeline & Clinical Trials

DMD Voice: Qualitative Interviews With Patients and Caregivers

Duchenne Muscular Dystrophy (DMD)

N/A

Clinical Trials (1)

NCT06925269DMD Voice: Qualitative Interviews With Patients and Caregivers

N/A

Nanoone Woman Underwear

Dysmenorrhea

N/A

Clinical Trials (1)

NCT01449305Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea

N/A

Placebo

Prediabetes

N/A

Clinical Trials (1)

NCT02300181Effect of the Extract of the Flour Fermented With Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose

N/A

Sixty device

End Stage Renal Disease

N/A

BOSCOGEN 18% Protein ONS: Energy 480 kcal, Protein 21.6 g, BCAA 6000 mg, Omega-3 fatty acid 1.8 g, fiber 5 g

ESRD (End-Stage Renal Disease)

N/A

Clinical Trials (1)

NCT07060040The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status

N/A

Screening for DM, ASCVD, MetS and OSAS

Diabetes Mellitus

N/A

Clinical Trials (1)

NCT03459638Periodontitis as Signal for an Underlying Disease

N/A

Online disease surveillance data access

Communicable Diseases

N/A

Clinical Trials (1)

NCT01232686Snow Disease Surveillance System Study

N/A

NEAA

Metabolism

N/A

Clinical Trials (1)

NCT05020808The Effect of a Plant Protein Isolate on Muscle Protein Synthesis in Humans at Rest and After Resistance Exercise

N/A

Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule

Acne Vulgaris

N/A

Clinical Trials (1)

NCT05855629"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."

N/A

Light Intervention

Myopia

N/A

Clinical Trials (1)

NCT06631339Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

multidisciplinary treatment

Acute Admitted Multimorbid Patients

N/A

Clinical Trials (1)

NCT02336113Oslo Pharmacist Intervention Study - Effect on Readmissions

N/A

Eefooton oral solution

Chronic Kidney Diseases

N/A

Clinical Trials (1)

NCT05227313Double-Blind, Placebo-Controlled Trial of Eefooton in Patients With Chronic Kidney Disease

N/A

Clinical Evaluation

Buccal Mucosa Cancer

N/A

Clinical Trials (1)

NCT03137953Role of Imaging to Predict the Deep Surgical Margin in Gingivobuccal Complex Tumors

N/A

Intervention with Microfinance for AIDS and Gender Equity

HIV Infections

N/A

Clinical Trials (1)

NCT00242957The Intervention With Microfinance for AIDS and Gender Equity (IMAGE) Study

N/A

Modified Trans-Esophageal Prosthesis

Laryngeal Cancer

N/A

Clinical Trials (1)

NCT03039465A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients

N/A

SynEx Wound Cleanser

Wound Heal

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Commercial Kombucha tea

Schizophrenia

N/A

Clinical Trials (1)

NCT06502509Kombucha Tea for Improving Defecation in Patients With Schizophrenia- a Randomized Controlled Study

N/A

F-Point

Low Fibrinogen

N/A

Clinical Trials (1)

NCT03623061F-Point Validation Study

N/A

Pea-protein concentrate

Bioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy Men

N/A

Clinical Trials (1)

NCT04872530Bioavailability of Plant Protein Amino Acids

N/A

Patient Pathway Pharmacist intervention

Hip Fractures

N/A

Clinical Trials (1)

NCT03695081Patient Pathway Pharmacist - Optimal Drug-related Care

N/A

SEE Change Business and Personal Agency Training

Well-Being, Psychological

N/A

Clinical Trials (1)

NCT05958225SEE Change Evaluation - Impacts of Personal Agency Training on Ugandan Entrepreneurs

N/A

Compression Therapy System Prototype

Venous Leg Ulcer

N/A

Clinical Trials (1)

NCT05610241Preliminary Investigation of a Smart Compression Therapy Prototype

N/A

19 gauge needle

Sarcoidosis

N/A

nCLE aided RANB biospy

Lung Neoplasms

N/A

Combined Plant-Based Protein and Marine-Based Multi-Mineral Supplement

Bone Resorption

N/A

Clinical Trials (1)

NCT05533502Combination Plant-Based Protein and Marine-Based Multi-Mineral Supplement and Bone Remodeling in Young Adults

N/A

Inhalation technique training and discharge service

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT03691324Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study

N/A

3 doses of HPV 16/18 bivalent vaccine

Cervical Intraepithelial Neoplasia

N/A

Remote Administration of NSAA

Duchenne Muscular Dystrophy

N/A

MICS CABG

Coronary Artery Disease

N/A

Clinical Pharmacist Intervention

Severe Mental Illness

N/A

Transcranial Electric Stimulation

Sleep

N/A

Clinical Trials (1)

NCT07608614Sleep and Performance

N/A

In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Aci

Cardiovascular Diseases

N/A

Clinical Trials (1)

NCT01777516In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid

N/A

NUIG OAB App

Overactive Bladder

N/A

Clinical Trials (1)

NCT05170100Evaluating a Digital Intervention for Overactive Bladder

N/A

Premium Amino Acids

Colorectal Cancer

N/A

Clinical Trials (1)

NCT04567459The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study

N/A

Water Control

Insulin Resistance

N/A

Clinical Trials (1)

NCT03102463The Role of Milk Derived Peptides on Glycaemic Control

N/A

Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers

COPD

N/A

Clinical Trials (1)

NCT02490358Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers

N/A

Scales

Stroke

N/A

Clinical Trials (1)

NCT02793934The Pilot Project Development Of MEdical Rehabilitation System in Russian Federation

N/A

Active breaks

Physical Activity

N/A

KneeStim

Anterior Cruciate Ligament Injuries

N/A

Clinical Trials (1)

NCT06341868Dynamic Muscular Electrical Stimulation Following Anterior Cruciate Ligament Reconstruction in Military Academy Cadets

N/A

Pharmacogenetic test

Admitted Multimorbid Patients

N/A

Clinical Trials (1)

NCT04573491Implementation of Pharmacogenetic Testing in Hospital Wards

N/A

rice protein RP-80N

Healthy

N/A

Clinical Trials (1)

NCT05560048Anti-exercise-fatigue Effects of Rice Protein RP-80NY in Men

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Transforming Powder Dressing

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT05046158Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care

N/A

Dynamic Lighting

Sleep

N/A

Clinical Trials (1)

NCT05697757Lighting for Older Adults With Dementia

N/A

Medication reconciliation at the ICU

Medicines Reconciliation

N/A

Clinical Trials (1)

NCT03173690Medicines Reconciliation at an Intensive Care Unit

N/A

RiSolve

Overactive Bladder (OAB)

N/A

Clinical Trials (1)

NCT07206446A Prospective Evaluation of a Prescription Digital Therapeutic for Treatment of Overactive Bladder in Women: The RiSolve Trial

N/A

A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Prev

Cardiovascular Diseases

N/A

Recombinant Human Papillomavirus Nonavalent

Cervical Cancer

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 33 approved products, 52 clinical trials

Top TAs: Oncology, Immunology, Infectious Diseases

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Peak3 (9%)

LOE Approaching13 (39%)

Post-LOE17 (52%)

33 total products

Therapeutic Area Focus

8 marketed6 pipeline

8 marketed

3 marketed3 pipeline

3 marketed1 pipeline

Hiring Trend

Actively Hiring

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2025-02-28

77 employees affected— Earth City, MO

Source: state DOL filings, aggregated via Big Local News

77-employee facility closure in Earth City, MO effective Feb 2025 signals active restructuring and ongoing workforce contraction.

Active layoff activity in a public company signals material business stress; organizational stability is compromised and further cuts may follow.

hydrocortisone acetate cream

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic, and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressing substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressing may be a valuable therapeutic adjunct for the treatment of resistant dermatoses. ( ) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

2 marketed2 pipeline

Respiratory

2 marketed2 pipeline

Neurology

1 marketed2 pipeline

Rare Diseases

3 pipeline

Enterprise Therapeutics

About Enterprise Therapeutics

Why Work Here

Key Products

Watch Out For

Products & Portfolio (15)

Key Products by Revenue

Other Products (7)

Pipeline & Clinical Trials

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)